Welcome to Broadline Capital
Formed two decades ago, Broadline Capital is a global alternative investment firm focused primarily on providing capital and strategic support for category leaders and category creators that are reshaping their industry.
Broadline is inspired by champions — people of vision and courage — whose ideas can positively change the world, and who are ready to transform their business into the next big, industry-changing company. The investment team seeks purpose-driven companies that are positioned to create broad impact as the world continues to transition toward an economy increasingly driven by the pursuit of a more Efficient, Sustainable, and Healthier way of life — placing emphasis on companies whose Addressable Markets are large enough to represent a promising commercial opportunity.
Broadline's principals have spent their entire careers building trust-based relationships globally. Most of them previously launched and developed successful companies, where they led some of the most creative deals in the history of their respective categories and negotiated quality exits on behalf of themselves and their investors. Their combined access to domain expertise, pragmatic operating experience, and a vast network of relationships built over many years, help them to add value for Broadline's current portfolio companies. They believe the firm's current opportunities are among the most exciting on the planet.
New York | Miami | San Diego | Boulder | Columbus | Seoul | Shanghai | London
Broadline's proprietary investment process is designed to stretch alpha at every link of the investment value chain. The investment team seeks diversification by investing across a range of industries, geographies, transaction structures, and market capitalizations. When selecting opportunities, they take a two-pronged approach:
First, the investment team starts with a "Top-Down" approach to identify Core Thematic Categories where the combination of strong margins, industry growth, and broad impact are creating an abundance of opportunities targeting Large Addressable Markets.
Next, they take a "Bottom-Up" approach to screen for companies that are tracking to become Category Leaders or Category Creators, placing emphasis on companies expecting a near-term liquidity event or valuation milestone, such as an IPO or M&A event.
Areas of Focus
Sustainability & Environment. Supporting how the world comes together to reduce Greenhouse Gas (GHG) pollution. Accelerating widespread conversion to green-powered Commercial Transportation and Industrial Equipment.
Purpose-driven Technologies. Advancing innovations that increase efficiency, precision, convenience, accessibility, and data security. Addressing unmet needs through profitable business models that creatively apply tools based on SaaS, Blockchain, Robotics, and Business Process Automation.
Financial Services. Unlocking value-added service offerings through the use of digital solutions that are Smarter, Faster, and more Accessible.
Healthcare. Advancing novel therapeutic platforms, machine learning tools, synthetic biologic innovations, and less-invasive medical devices to help improve Patient Outcomes.
Food System. Upgrading the food ecosystem through innovations that increase Production Efficiencies, Supply Chain Resilience, Source Traceability, and Ingredient Transparency. Supporting opportunities that convert Food Waste into Carbon Credits.
We invite you to scroll through case examples below. If you're a Broadline-registered investor, please click on the "Investor Login" tab at the top of this website for management reports from portfolio companies.
GLP-1 TREATMENT ALTERNATIVE VIA NOVEL ENDOSCOPIC Device PLATFORM
EndoSphere is a clinical-stage medical technology company that has developed a first-in-class, less-invasive device platform to treat metabolic diseases, including one of the world's largest and fastest-growing healthcare categories: Obesity and its co-morbidities including Fatty Liver Disease. EndoSphere's novel "Endo-Metabolic" device platform presents a completely new category, and the first to uniquely focus on the Duodenum (the upper intestinal organ), widely recognized as the body's Metabolic Control Center. Endosphere's flagship anti-obesity device, called KB-21, is incisionless, reversible and repeatable. In clinical studies, the device has amplified GLP-1 hormone levels and enabled Obese patients to achieve significant Excess Weight Loss (EWL) without the need for riskier treatment alternatives. Unlike restrictive devices and bariatric surgeries, which typically work by reducing the available capacity of the stomach, EndoSphere's devices work at a physiological level by triggering the body to amplify hormonal responses to food intake. Unlike GLP-1 drugs based on synthetic hormones, EndoSphere's device amplifies the body's release of its own hormones. The result: A more natural approach to accelerate satiation, recalibrate brain-gut metabolic feedback loops, and rebalance insulin levels. EndoSphere's proprietary technologies and patented solutions are 100% company-owned (free from any third-party licensing or royalty obligations). EndoSphere's industry recognitions include the "Fierce15" award which annually aims to recognize the world's most promising privately-held medical innovations. For more information, visit https://www.Endo-sphere.com.
Energy & Environment
Carbon-Free Lithium-ion and Solid State BatterY CATHODES
Powermers Inc. is an Energy Storage innovator and Advanced Materials company that has created fundamental advancements in lithium-ion and solid state battery cathode technologies. The company has created the world's first (and only) Carbon-Free Lithium-ion and Solid State Battery Cathodes by replacing inactive materials (including carbon, binders and solvents) with proprietary nano-scale polymer coatings. Powermers' drop-in technology enables efficient adoption by battery manufacturers. Replacing inactive deadweight materials with safer, higher-performing conductive nano-scale polymers has produced differentiated results in performance. These fundamental advancements in cathode technology have been independently tested and validated by government labs (CERL) and universities around the world, including the Center for Automotive Research at The Ohio State University, and have been published in industry peer-review publications including American Chemical Society's Applied Materials & Interfaces. Independently-validated lab results of not only coin cell batteries but also scaled pouches demonstrate Powermers' low-cost transition-metal polymers to provide higher catalytic functionality than pure noble-metal catalysts, including gold, platinum, and palladium. Powermers' advanced polymer technology platform creates the 7-point Powermers Advantage:
1. Safety: Mitigates Thermal Runaway Risk (the prevailing cause of combustion in high-voltage Lithium-ion batteries).
2. Toxicity: Reduces reliance on costly Toxic Solvents frequently used in battery manufacturing processes.
3. Energy ("How far can you go"): Expands Active Material Limits by replacing inactive materials with conductive polymers.
4. Power ("How fast can you go"): No sacrifice of Power is necessary.
5. Cycle Life ("How long can your battery last"): No sacrifice of Cycle Life is necessary.
6. Adoption ("Ease of adoption by manufacturers"): Drop-in technology enables rapid adoption into existing battery manufacturers' processes.
7. Cost per KWH: Reduces Total Cost per KWH by eliminating reliance on costly solvents while enabling increased energy.
For more information, please visit https://www.Powermers.com.
Broadline Capital's principals and venture partners have spent their entire careers building trust-based relationships globally, and have led some of the most creative deals in the history of their respective categories. They understand what it takes to align multiple stakeholders toward a shared vision, develop a clear plan and execute it, because they've done it.
Broadline's principals love going back to their roots as entrepreneurs by collaborating with inspired management teams to achieve a shared vision.
Most of the principals are past CEOs and entrepreneurs who created significant value in their prior companies and achieved quality exits on behalf of themselves and their investors. They've excelled in prior careers at top institutions such as McKinsey, Morgan Stanley, General Electric, Apple, Brunswick, Oppenheimer, PwC, Allergan, Pfizer, and Roche. They trained and taught at leading educational and research institutions. They've collectively received 46 academic degrees - including 21 advanced degrees and 11 doctorates. Their combined experience, expertise and network of relationships help contribute strategic value for supported portfolio companies.
"At Broadline Capital, we are inspired by champions – people of vision and courage – whose ideas can positively change the world, and who are working to transform their ideas into the next big, industry-changing company." If you share our perspective, we invite you to join us. Please direct inquiries to: email@example.com.